<h1>Pharmaceuticals trade deal secures zero tariffs on medicines for three years, tied to increased manufacturer investment commitments.</h1> A bilateral arrangement grants a zero-tariff rate on UK-origin pharmaceuticals, pharmaceutical ingredients, and medical technology exported to the United States for at least three years, conditioned on UK drug firms increasing investment and job creation in the United States and on the UK government increasing spending on new treatments.